Title: Per Holm: Innovator in Immunosuppressive Treatments
Introduction
Per Holm is a notable inventor based in Denmark, recognized for his contributions to the field of immunosuppressive treatments. His innovative work primarily focuses on the development of extended release oral dosage forms of tacrolimus, a critical medication for transplant patients.
Latest Patents
Holm's latest patents include significant advancements in the formulation of tacrolimus for improved treatment of transplant patients. One of his patents describes an extended release oral dosage form that comprises tacrolimus or a pharmaceutically active analogue. This formulation is designed for once-daily immunosuppressive treatment, particularly for kidney or liver transplant patients. The dosage form is engineered to release the active substance over an extended period, resulting in improved pharmacokinetic parameters. These enhancements include decreased peak concentrations, increased bioavailability, extended times for maximal concentration, and higher minimal concentrations compared to conventional immediate release dosage forms. Another patent focuses on a similar extended release dosage form, emphasizing the controlled release of the active substance over a defined period.
Career Highlights
Throughout his career, Per Holm has worked with prominent companies in the pharmaceutical industry, including Lifecycle Pharma A/S and Veloxis Pharmaceuticals A/S. His work has significantly impacted the development of medications that improve the quality of life for transplant patients.
Collaborations
Holm has collaborated with various professionals in the field, including Anders Buur and Michiel Onne Elema. These collaborations have contributed to the advancement of his innovative projects and the successful development of new pharmaceutical formulations.
Conclusion
Per Holm's contributions to the field of immunosuppressive treatments through his innovative patents and collaborations highlight his commitment to improving patient care. His work continues to influence the pharmaceutical industry and enhance the lives of transplant patients.